Gentofte Hospital

Running trials

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· Source

• Recruiting

  Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  NCT07770841· Phase 3· Source

• Recruiting

  Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

  NCT06892210· Phase 4· Source

• Recruiting

  AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  NCT07339423· Phase 3· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Source

• Recruiting

  The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT)

  2025-522528-29-00· Phase 2· Source

• Recruiting

  Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

  NCT07267949· Phase 2· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Source

• Active, not recruiting

  A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

  NCT06780449· Phase 3· Source

• Not yet recruiting

  Weight management with orismilast alone or in combination with s.c. semaglutide (WELOSITI)

  2024-517463-23-00· Phase 2· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Active, not recruiting

  DAPHNE

  2024-510746-14-00· Phase 4· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Source

• Recruiting

  Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

  NCT06401616· Phase 4· Source

• Active, not recruiting

  The Colchicine heart failure preserved trial

  2023-506207-26-00· Phase 3· Source

• Active, not recruiting

  Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial

  2022-502038-23-00· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Source

• Recruiting

  The Colchicine and atrial fibrillation trial

  2022-500850-40-01· Phase 3· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Source

• Recruiting

  COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

  NCT05633810· Phase 3· Source

• Recruiting

  Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms

  NCT05028153· Phase 2· Source

• Not yet recruiting

  A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)

  2024-517040-65-02· Phase 1/2· Source

• Recruiting

  ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO

  NCT03563417· Source

• Active, not recruiting

  Pulmonary Fibrosis Biomarker Cohort - a Prospective Cohort of Incident Patients With IPF

  NCT02755441· Source

• Active, not recruiting

  Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay

  NCT02772549· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Obesity2 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Psoriasis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

  NCT07373236· Source

• Completed

  The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes

  NCT06881472· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Active, not recruiting

  Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-508235-31-00· Phase 3· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Source

• Completed

  Using live vaccines to induce beneficial innate immune training and reduce systemic inflammation in COPD patients

  2023-504519-34-01· Phase 2· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Source

• Active, not recruiting

  Dapiglutide for the Treatment of Obesity

  NCT05788601· Phase 2· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Source

• Completed

  A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator

  NCT05752487· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Active, not recruiting

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· Phase 3· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  2023-507093-40-00· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Source

• Completed

  Eosinophil-guided Reduction of Inhaled Corticosteroids

  NCT04481555· Phase 4· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· Source

• Completed

  DANHEART (H-HeFT and Met-HeFT)

  NCT03514108· Phase 4· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Source